ENDLOS-TURBO CALL - FORMYCON Stock

Certificat

DE000DJ8JZD0

Market Closed - Boerse Frankfurt Warrants 03:35:09 2024-06-14 pm EDT
1.44 EUR -14.29% Intraday chart for ENDLOS-TURBO CALL - FORMYCON
Current month+18.85%
1 month+23.93%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-14 1.45 -13.69%
24-06-13 1.68 +1.82%
24-06-12 1.65 -2.37%
24-06-11 1.69 -6.11%
24-06-10 1.8 +4.65%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 03:35 pm EDT

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying FORMYCON AG
Issuer DZ BANK
WKN DJ8JZD
ISINDE000DJ8JZD0
Date issued 2024-01-17
Strike 31.7
Maturity Unlimited
Parity 10 : 1
Emission price 2.046
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.59
Lowest since issue 0.63

Company Profile

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
Sector
-
More about the company

Ratings for Formycon AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Formycon AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
46.25 EUR
Average target price
85.56 EUR
Spread / Average Target
+84.98%
Consensus